Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis
1 other identifier
observational
1
1 country
1
Brief Summary
In this study, the investigators will dynamically detect the expression of an immune regulator- T cell Ig and mucin domain protein 3 (Tim-3) in patient with sepsis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2013
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2013
CompletedFirst Submitted
Initial submission to the registry
July 1, 2014
CompletedFirst Posted
Study publicly available on registry
July 2, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedJanuary 28, 2016
January 1, 2016
1.7 years
July 1, 2014
January 26, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
all cause mortality
28 days
Study Arms (4)
normal control
healthy people
sepsis
mild response to infection
severe sepsis
infection with at least one organ dysfunction
septic shock
patients with septic shock
Eligibility Criteria
patients with sepsis
You may qualify if:
- More than one of the following:
- clinical manifestations: (1) a body temperature greater than 38℃ or less than 36℃; (2) a heart rate greater than 90 beats/minute; (3)tachypnea, manifested by a respiratory rate greater than 20 breaths per minute, or hyperventilation, as indicated by a PaCO2 of less than 32 mmHg; and (4)an alteration in the white blood cell count, such as a count greater than 12×10\^9/L, a count less than 4×10\^9/L, or the presence of more than 10 percent immature neutrophils
You may not qualify if:
- (1)patients younger than 18 years of age; (2)agranulocytosis (granulocyte counts,0.5×10\^9/L); (3) those discharged within 24 h; (4) those diagnosed with HIV infection or cancer; and (5) patients who refused to participate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Related Publications (1)
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003 Apr;29(4):530-8. doi: 10.1007/s00134-003-1662-x. Epub 2003 Mar 28.
PMID: 12664219BACKGROUND
Biospecimen
peripheral blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lixin Xie, PhD & MD
Head of Department of Respiratory Medicine,Chinese PLA Gerneral Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- doctor of Department of Respiratory Medicine
Study Record Dates
First Submitted
July 1, 2014
First Posted
July 2, 2014
Study Start
December 1, 2013
Primary Completion
August 1, 2015
Study Completion
December 1, 2015
Last Updated
January 28, 2016
Record last verified: 2016-01